1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Infectitious Diarrhea - Pipeline Review, H1 2014

Infectitious Diarrhea - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 76 pages

Infectitious Diarrhea - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Infectitious Diarrhea - Pipeline Review, H1 2014’, provides an overview of the Infectitious Diarrhea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Infectitious Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Infectitious Diarrhea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Infectitious Diarrhea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Infectitious Diarrhea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Infectitious Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Infectitious Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Infectitious Diarrhea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Infectitious Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Infectitious Diarrhea - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Infectitious Diarrhea Overview 7
Therapeutics Development 8
Pipeline Products for Infectitious Diarrhea - Overview 8
Pipeline Products for Infectitious Diarrhea - Comparative Analysis 9
Infectitious Diarrhea - Therapeutics under Development by Companies 10
Infectitious Diarrhea - Therapeutics under Investigation by Universities/Institutes 12
Infectitious Diarrhea - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Infectitious Diarrhea - Products under Development by Companies 16
Infectitious Diarrhea - Products under Investigation by Universities/Institutes 17
Infectitious Diarrhea - Companies Involved in Therapeutics Development 18
Actelion Ltd 18
Cubist Pharmaceuticals, Inc. 19
Pfizer Inc. 20
Paratek Pharmaceuticals, Inc. 21
Napo Pharmaceuticals, Inc. 22
MGB Biopharma Limited 23
Infectitious Diarrhea - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
surotomycin - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
crofelemer DR - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
fidaxomicin - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
cadazolid - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
fidaxomicin - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
AKT-10081 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
MGB-BP-3 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
PF-06425090 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Capsule Conjugate Vaccine for Campylobacter Caused Diarrhea - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Tetracycline Derivatives For CDAD - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
PZ-7475 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Clostridium difficile Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Enterotoxigenic Escherichia coli Vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Fucosylated Glycoproteins - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Infectitious Diarrhea - Recent Pipeline Updates 57
Infectitious Diarrhea - Dormant Projects 70
Infectitious Diarrhea - Product Development Milestones 71
Featured News and Press Releases 71
Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation 71
Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy 71
May 28, 2013: Antidiarrheal drug candidate moves to next phase of clinical study 72
Dec 21, 2012: Actelion's Cadazolid To Move Into Phase III Clinical Development In Patients With Clostridium Difficile Associated Diarrhea 73
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-315 At ICAAC 2012 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables

Number of Products under Development for Infectitious Diarrhea, H1 2014 8
Number of Products under Development for Infectitious Diarrhea - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Infectitious Diarrhea - Pipeline by Actelion Ltd, H1 2014 18
Infectitious Diarrhea - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 19
Infectitious Diarrhea - Pipeline by Pfizer Inc., H1 2014 20
Infectitious Diarrhea - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 21
Infectitious Diarrhea - Pipeline by Napo Pharmaceuticals, Inc., H1 2014 22
Infectitious Diarrhea - Pipeline by MGB Biopharma Limited, H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Infectitious Diarrhea Therapeutics - Recent Pipeline Updates, H1 2014 57
Infectitious Diarrhea - Dormant Projects, H1 2014 70

List of Figures

Number of Products under Development for Infectitious Diarrhea, H1 2014 8
Number of Products under Development for Infectitious Diarrhea - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.